Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
68Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE).
Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, Seidensticker M, Ricke J, Schmid-Tannwald C. Ingenerf M, et al. Cancers (Basel). 2021 Aug 27;13(17):4321. doi: 10.3390/cancers13174321. Cancers (Basel). 2021. PMID: 34503131 Free PMC article.
Diagnostic Workup for Patients with Solid Renal Masses: A Cost-Effectiveness Analysis.
Runtemund J, Rübenthaler J, von Münchhausen N, Ingenerf M, Grawe F, Biechele G, Gassert FG, Tollens F, Rink J, Cecatka S, Schmid-Tannwald C, Froelich MF, Clevert DA, Schnitzer ML. Runtemund J, et al. Among authors: ingenerf m. Cancers (Basel). 2022 Apr 29;14(9):2235. doi: 10.3390/cancers14092235. Cancers (Basel). 2022. PMID: 35565365 Free PMC article.
Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
Schnitzer ML, Buchner J, Biechele G, Grawe F, Ingenerf M, von Münchhausen N, Kaiser CG, Kunz WG, Froelich MF, Schmid-Tannwald C, Rübenthaler J. Schnitzer ML, et al. Among authors: ingenerf m. Eur J Radiol. 2023 Jun;163:110803. doi: 10.1016/j.ejrad.2023.110803. Epub 2023 Mar 30. Eur J Radiol. 2023. PMID: 37004464
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: ingenerf m. Cytotherapy. 2023 Sep;25(9):986-992. doi: 10.1016/j.jcyt.2023.03.007. Epub 2023 Apr 11. Cytotherapy. 2023. PMID: 37055322
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Among authors: ingenerf m. Cancer Imaging. 2023 May 15;23(1):44. doi: 10.1186/s40644-023-00566-7. Cancer Imaging. 2023. PMID: 37189191 Free PMC article.
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT.
Ingenerf M, Grawe F, Winkelmann M, Karim H, Ruebenthaler J, Fabritius MP, Ricke J, Seidensticker R, Auernhammer CJ, Zacherl MJ, Seidensticker M, Schmid-Tannwald C. Ingenerf M, et al. Diagn Interv Imaging. 2024 Jan;105(1):15-25. doi: 10.1016/j.diii.2023.06.007. Epub 2023 Jul 13. Diagn Interv Imaging. 2024. PMID: 37453859
21 results